Chonluten

updated

Chonluten is the tripeptide Glu-Asp-Gly from the Khavinson group of Russian short-peptide bioregulators, sold for lung health and used with or instead of Bronchogen. No controlled human study exists, and its one published experiment is in a human leukemia monocyte cell line, not lung tissue. The group's own classification table lists it as a gastroprotector and stress protector and gives it no bronchial role.

Synthetic tripeptide bioregulator

  • Chonluten is the tripeptide Glu-Asp-Gly (EDG), laboratory code T-34: PubChem CID 194641, C11H17N3O8, molecular weight 319.27, CAS 75007-24-8. PubChem has no record under the name Chonluten.
  • One PubMed record uses the name Chonluten: a 2022 experiment in human THP-1 leukemia monocytes and macrophages, where it was one of five peptides tested at 100 ng/mL.
  • That paper cites two non-lung references for a respiratory role. The group's own 2022 table lists Chonluten as a gastroprotector and a stress protector and gives no bronchial role.
  • In organotypic skin explants from young rats, four of five synthesized tripeptides stimulated proliferation; the exception was T-34, the Glu-Asp-Gly peptide.
  • No study tested Chonluten with Bronchogen. They are different peptides, a tripeptide and a tetrapeptide.
  • A PubMed search on 10 October 2026 for chonluten restricted to clinical trial or randomized controlled trial publication types returned 0 records.

What is Chonluten, and is it an approved drug?

Chonluten is the synthetic tripeptide Glu-Asp-Gly (EDG), also coded T-34, from the Khavinson group. PubChem has no record under the name, so the name is tied to the sequence by the literature. openFDA Drugs@FDA and DailyMed return no product under the name, so no FDA record of it was found.

PubChem has no record under the name Chonluten. The tripeptide Glu-Asp-Gly is CID 194641, C11H17N3O8, molecular weight 319.27, CAS 75007-24-8, and its synonym list includes T-34 tripeptide. A 2012 abstract from the group defines its laboratory code T-34 as Glu-Asp-Gly. The trade name Chonluten is tied to the sequence by the literature, not by PubChem: the only PubMed record that uses the name says in its methods that Chonluten is the tripeptide Glu-Asp-Gly, and that it and two other Khavinson peptides were synthesized on the basis of their natural counterparts from animal organs. The group's 2022 table of ultrashort peptides lists Chonluten (EDG).

The link between the code T-34 and the name Chonluten rests on PubChem's synonym and the group's own table, not on a paper that states both. The sequence behind the code is established by the 2012 abstract. One PubMed record is the whole body of work under this trade name.

The lung role is thinly sourced, and the group labels the compound differently. The 2022 THP-1 paper calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, but the two references it cites for that are a 2017 study of EDR and KED peptides on neuronal spines in an Alzheimer's cell model and a 2013 study of Vilon in thymus cells, and neither is a lung study. The group's own 2022 table classifies Chonluten as a gastroprotector, citing a 2012 abstract on peptide T-34 in gastric ulcer, and as a stress protector, citing a US patent, and it lists no bronchial role.

On 10 October 2026 openFDA Drugs@FDA and DailyMed returned no product under the name Chonluten, and ClinicalTrials.gov returned no study for Chonluten or for an EDG tripeptide. That covers FDA and registry sources and says nothing about other regulators.

PubChem: Glu-Asp-Gly tripeptide identity

Chemical identity record

National Library of Medicine. PubChem compound record CID 194641.

A PubChem name search for Chonluten returned no record. The tripeptide Glu-Asp-Gly is CID 194641, C11H17N3O8, molecular weight 319.27, CAS 75007-24-8, and its synonym list includes T-34 tripeptide. A 2012 abstract from the group defines its laboratory code T-34 as Glu-Asp-Gly (PMID 22803085). The trade name Chonluten is tied to the sequence by the literature, not by PubChem.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined synthetic peptide
Follow-up
Not applicable
Study design
NLM chemical record
Funding
not stated in the source

The record defines the sequence. It does not carry the name Chonluten.

Read the original source
2022 THP-1 paper: the only record under the name Chonluten

Cell study

Avolio F et al. Int J Mol Sci. 2022;23(7). PMID 35408963.

The only PubMed record that uses the name Chonluten says in its methods that Chonluten is the tripeptide Glu-Asp-Gly, and that it and two other Khavinson peptides were synthesized on the basis of their natural counterparts from animal organs. Human THP-1 monocytes and THP-1-derived macrophages were treated with 100 ng/mL of each of five Khavinson peptides, including Chonluten, alone or with 100 ng/mL lipopolysaccharide. All five peptides raised tyrosine phosphorylation of mitogen-activated kinases, inhibited lipopolysaccharide-stimulated TNF and IL-6 expression in differentiated cells, and reduced THP-1 adhesion to lipopolysaccharide-activated endothelial cells. The abstract says Chonluten inhibited TNF production of monocytes exposed to lipopolysaccharide. The results text adds that Chonluten alone produced a slight release of TNF in proliferating monocytes and that a moderate percentage of THP-1 cells showed an apoptotic profile with it. The paper calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, citing two references that are not lung studies: a 2017 study of EDR and KED peptides on neuronal spines in an Alzheimer's cell model and a 2013 study of Vilon in thymus cells.

Participants / model
Human THP-1 leukemia monocytic cell line and THP-1-derived macrophages; HUVEC endothelial cells
Treatment
Peptide at 100 ng/mL in culture medium
Follow-up
not stated in the source
Study design
Cell-line experiment series with five peptides
Funding
not stated in the source

A human leukemia cell line, not lung tissue. Chonluten was one of five peptides in a single experiment series.

Read the original source
2022 table: Chonluten (EDG) listed as gastroprotector and stress protector

Narrative review

Khavinson V et al. Int J Mol Sci. 2022;23(14). PMID 35887081.

The group's 2022 table of ultrashort peptides lists Chonluten (EDG). It classifies Chonluten as a gastroprotector, citing a 2012 abstract on peptide T-34 in gastric ulcer, and as a stress protector, citing a US patent, and it lists no bronchial role. The 2022 THP-1 paper, by contrast, calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, citing two references that are not lung studies.

Participants / model
Not applicable
Treatment
Not applicable
Follow-up
not stated in the source
Study design
Review table
Funding
not stated in the source

The group's own classification gives Chonluten gastric and stress roles, not a bronchial one.

Read the original source
2012 skin explants: T-34 (Glu-Asp-Gly) did not stimulate proliferation

Cell study

Voicekhovskaya MA et al. Bull Exp Biol Med. 2012;152(3):357-9. PMID 22803085.

A 2012 abstract lists synthesized tripeptides T-32 (Glu-Asp-Ala), T-33 (Glu-Asp-Arg), T-34 (Glu-Asp-Gly), T-36 (Glu-Asp-Pro) and T-38 (Lys-Glu-Asp). In organotypic skin explants from young rats, all stimulated cell proliferation except T-34, the Glu-Asp-Gly peptide, which did not. In skin explants from old rats only T-38 produced a marked stimulatory effect.

Participants / model
Organotypic skin explants from young and old rats
Treatment
Peptides in culture medium
Follow-up
not stated in the source
Study design
Organotypic explant culture, proliferation and p53 expression
Funding
not stated in the source

A negative cell result for the same tripeptide. The study is about skin, in rats, in explants, and the abstract does not use the name Chonluten.

Read the original source
PubMed: 1 record, no clinical trial, no lung or combination study

PubMed search record

PubMed searches run 10 October 2026: chonluten[tiab]; chonluten restricted to clinical trial or randomized controlled trial publication types; chonluten, Glu-Asp-Gly or EDG combined with bronchogen, Ala-Glu-Asp-Leu or AEDL. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for chonluten[tiab] returned 1 record, the THP-1 paper, and chonluten restricted to clinical trial or randomized controlled trial publication types returned 0 records. A search combining chonluten, Glu-Asp-Gly or EDG with bronchogen, Ala-Glu-Asp-Leu or AEDL returned 4 records, all general Khavinson peptide papers that list several peptides (for example DNA-binding and transporter work); none compares or combines the two. ClinicalTrials.gov returned no study for Chonluten or for an EDG tripeptide. openFDA Drugs@FDA and DailyMed return no product under the name. The searches found no study under the name in lung tissue, in an airway disease model, in an animal, or in a person.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

What have the cell and tissue studies found?

The only experiment under the name Chonluten is in a human leukemia monocyte cell line, where it was one of five peptides that lowered TNF and IL-6 after lipopolysaccharide. No study under the name in lung tissue, an airway disease model or an animal was found, and the same tripeptide under the code T-34 did not stimulate proliferation in young rat skin explants.

Human THP-1 monocytes and THP-1-derived macrophages were treated with 100 ng/mL of each of five Khavinson peptides, including Chonluten, alone or with 100 ng/mL lipopolysaccharide. All five peptides raised tyrosine phosphorylation of mitogen-activated kinases, inhibited lipopolysaccharide-stimulated TNF and IL-6 expression in differentiated cells, and reduced THP-1 adhesion to lipopolysaccharide-activated endothelial cells. The abstract says Chonluten inhibited TNF production of monocytes exposed to lipopolysaccharide. The results text adds that Chonluten alone produced a slight release of TNF in proliferating monocytes and that a moderate percentage of THP-1 cells showed an apoptotic profile with it. This is a human leukemia cell line, not lung tissue, and Chonluten was one of five peptides in a single experiment series.

A 2012 abstract reports that peptide T-34, described as a geroprotective peptide, regulates mRNA expression of various genes, and that in gastric ulcer it normalizes the synthesis of antioxidant and anti-inflammatory proteins by regulating the corresponding genes. The abstract does not state a species, dose, route, the sequence or the name Chonluten; the group's 2022 table cites it for Chonluten as a gastroprotector, and a separate 2012 abstract gives T-34 as Glu-Asp-Gly.

A negative cell result exists for the same tripeptide. In organotypic skin explants from young rats, the synthesized tripeptides T-32 (Glu-Asp-Ala), T-33 (Glu-Asp-Arg), T-34 (Glu-Asp-Gly), T-36 (Glu-Asp-Pro) and T-38 (Lys-Glu-Asp) all stimulated cell proliferation except T-34, the Glu-Asp-Gly peptide, which did not. In skin explants from old rats only T-38 produced a marked stimulatory effect. The study is about skin, in rats, in explants.

2022 THP-1 paper: the only record under the name Chonluten

Cell study

Avolio F et al. Int J Mol Sci. 2022;23(7). PMID 35408963.

The only PubMed record that uses the name Chonluten says in its methods that Chonluten is the tripeptide Glu-Asp-Gly, and that it and two other Khavinson peptides were synthesized on the basis of their natural counterparts from animal organs. Human THP-1 monocytes and THP-1-derived macrophages were treated with 100 ng/mL of each of five Khavinson peptides, including Chonluten, alone or with 100 ng/mL lipopolysaccharide. All five peptides raised tyrosine phosphorylation of mitogen-activated kinases, inhibited lipopolysaccharide-stimulated TNF and IL-6 expression in differentiated cells, and reduced THP-1 adhesion to lipopolysaccharide-activated endothelial cells. The abstract says Chonluten inhibited TNF production of monocytes exposed to lipopolysaccharide. The results text adds that Chonluten alone produced a slight release of TNF in proliferating monocytes and that a moderate percentage of THP-1 cells showed an apoptotic profile with it. The paper calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, citing two references that are not lung studies: a 2017 study of EDR and KED peptides on neuronal spines in an Alzheimer's cell model and a 2013 study of Vilon in thymus cells.

Participants / model
Human THP-1 leukemia monocytic cell line and THP-1-derived macrophages; HUVEC endothelial cells
Treatment
Peptide at 100 ng/mL in culture medium
Follow-up
not stated in the source
Study design
Cell-line experiment series with five peptides
Funding
not stated in the source

A human leukemia cell line, not lung tissue. Chonluten was one of five peptides in a single experiment series.

Read the original source
2012 abstract: peptide T-34 in gastric ulcer

Animal study

Khavinson VKh et al. Bull Exp Biol Med. 2012;152(5):615-8. PMID 22803148.

A 2012 abstract reports that peptide T-34, described as a geroprotective peptide, regulates mRNA expression of various genes, and that in gastric ulcer it normalizes the synthesis of antioxidant and anti-inflammatory proteins by regulating the corresponding genes. The abstract does not state a species, dose, route, the sequence, or the name Chonluten. The group's 2022 table cites this paper for Chonluten as a gastroprotector, and a separate 2012 abstract gives T-34 as Glu-Asp-Gly.

Participants / model
Gastric ulcer model, species not stated in the abstract
Treatment
Not stated in the abstract
Follow-up
not stated in the source
Study design
Preclinical report
Funding
not stated in the source

The abstract does not use the name Chonluten. The link to the trade name comes from the group's 2022 table.

Read the original source
2012 skin explants: T-34 (Glu-Asp-Gly) did not stimulate proliferation

Cell study

Voicekhovskaya MA et al. Bull Exp Biol Med. 2012;152(3):357-9. PMID 22803085.

A 2012 abstract lists synthesized tripeptides T-32 (Glu-Asp-Ala), T-33 (Glu-Asp-Arg), T-34 (Glu-Asp-Gly), T-36 (Glu-Asp-Pro) and T-38 (Lys-Glu-Asp). In organotypic skin explants from young rats, all stimulated cell proliferation except T-34, the Glu-Asp-Gly peptide, which did not. In skin explants from old rats only T-38 produced a marked stimulatory effect.

Participants / model
Organotypic skin explants from young and old rats
Treatment
Peptides in culture medium
Follow-up
not stated in the source
Study design
Organotypic explant culture, proliferation and p53 expression
Funding
not stated in the source

A negative cell result for the same tripeptide. The study is about skin, in rats, in explants, and the abstract does not use the name Chonluten.

Read the original source

Has Chonluten been tested in people?

No. A PubMed search on 10 October 2026 for chonluten returned 1 record, a cell-line paper, and restricting to clinical trial or randomized controlled trial publication types returned 0 records. ClinicalTrials.gov returned no study, and the searches found no study under the name in lung tissue, an airway disease model, an animal or a person.

A PubMed search for chonluten[tiab] returned 1 record, the THP-1 paper, and chonluten restricted to clinical trial or randomized controlled trial publication types returned 0 records. A search combining chonluten, Glu-Asp-Gly or EDG with bronchogen, Ala-Glu-Asp-Leu or AEDL returned 4 records, all general Khavinson peptide papers that list several peptides (for example DNA-binding and transporter work); none compares or combines the two.

ClinicalTrials.gov returned no study for Chonluten or for an EDG tripeptide, and openFDA Drugs@FDA and DailyMed return no product under the name. Across these searches there is no study under the name in lung tissue, in an airway disease model, in an animal or in a person.

PubMed: 1 record, no clinical trial, no lung or combination study

PubMed search record

PubMed searches run 10 October 2026: chonluten[tiab]; chonluten restricted to clinical trial or randomized controlled trial publication types; chonluten, Glu-Asp-Gly or EDG combined with bronchogen, Ala-Glu-Asp-Leu or AEDL. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for chonluten[tiab] returned 1 record, the THP-1 paper, and chonluten restricted to clinical trial or randomized controlled trial publication types returned 0 records. A search combining chonluten, Glu-Asp-Gly or EDG with bronchogen, Ala-Glu-Asp-Leu or AEDL returned 4 records, all general Khavinson peptide papers that list several peptides (for example DNA-binding and transporter work); none compares or combines the two. ClinicalTrials.gov returned no study for Chonluten or for an EDG tripeptide. openFDA Drugs@FDA and DailyMed return no product under the name. The searches found no study under the name in lung tissue, in an airway disease model, in an animal, or in a person.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Does Chonluten support lung health, with or instead of Bronchogen?

No direct support. The one paper that tested Chonluten used a human leukemia monocyte line and cited two non-lung references for its respiratory role. No study tested Chonluten with Bronchogen, and the group's own table gives Chonluten gastroprotector and stress protector roles, not a bronchial one.

Sellers promote Chonluten for lung health, used with or instead of Bronchogen. The one paper that tested Chonluten used a human leukemia monocyte line, not lung tissue, and Chonluten was one of five peptides in a single experiment series. It cited two non-lung references for the peptide's respiratory role.

No study tested Chonluten together with Bronchogen. A PubMed search combining chonluten, Glu-Asp-Gly or EDG with bronchogen, Ala-Glu-Asp-Leu or AEDL returned 4 records, all general Khavinson peptide papers that list several peptides; none compares or combines the two. They are different peptides, a tripeptide and a tetrapeptide, with different reported targets.

Any tissue-extract product sold under a similar name is a different thing from this synthetic peptide, and none was tested in the studies on this page. No PubMed record describes a Cytomax or Cytogen retail product, so nothing here is cited to those product lines.

2022 THP-1 paper: the only record under the name Chonluten

Cell study

Avolio F et al. Int J Mol Sci. 2022;23(7). PMID 35408963.

The only PubMed record that uses the name Chonluten says in its methods that Chonluten is the tripeptide Glu-Asp-Gly, and that it and two other Khavinson peptides were synthesized on the basis of their natural counterparts from animal organs. Human THP-1 monocytes and THP-1-derived macrophages were treated with 100 ng/mL of each of five Khavinson peptides, including Chonluten, alone or with 100 ng/mL lipopolysaccharide. All five peptides raised tyrosine phosphorylation of mitogen-activated kinases, inhibited lipopolysaccharide-stimulated TNF and IL-6 expression in differentiated cells, and reduced THP-1 adhesion to lipopolysaccharide-activated endothelial cells. The abstract says Chonluten inhibited TNF production of monocytes exposed to lipopolysaccharide. The results text adds that Chonluten alone produced a slight release of TNF in proliferating monocytes and that a moderate percentage of THP-1 cells showed an apoptotic profile with it. The paper calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, citing two references that are not lung studies: a 2017 study of EDR and KED peptides on neuronal spines in an Alzheimer's cell model and a 2013 study of Vilon in thymus cells.

Participants / model
Human THP-1 leukemia monocytic cell line and THP-1-derived macrophages; HUVEC endothelial cells
Treatment
Peptide at 100 ng/mL in culture medium
Follow-up
not stated in the source
Study design
Cell-line experiment series with five peptides
Funding
not stated in the source

A human leukemia cell line, not lung tissue. Chonluten was one of five peptides in a single experiment series.

Read the original source
2022 table: Chonluten (EDG) listed as gastroprotector and stress protector

Narrative review

Khavinson V et al. Int J Mol Sci. 2022;23(14). PMID 35887081.

The group's 2022 table of ultrashort peptides lists Chonluten (EDG). It classifies Chonluten as a gastroprotector, citing a 2012 abstract on peptide T-34 in gastric ulcer, and as a stress protector, citing a US patent, and it lists no bronchial role. The 2022 THP-1 paper, by contrast, calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, citing two references that are not lung studies.

Participants / model
Not applicable
Treatment
Not applicable
Follow-up
not stated in the source
Study design
Review table
Funding
not stated in the source

The group's own classification gives Chonluten gastric and stress roles, not a bronchial one.

Read the original source
PubMed: 1 record, no clinical trial, no lung or combination study

PubMed search record

PubMed searches run 10 October 2026: chonluten[tiab]; chonluten restricted to clinical trial or randomized controlled trial publication types; chonluten, Glu-Asp-Gly or EDG combined with bronchogen, Ala-Glu-Asp-Leu or AEDL. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for chonluten[tiab] returned 1 record, the THP-1 paper, and chonluten restricted to clinical trial or randomized controlled trial publication types returned 0 records. A search combining chonluten, Glu-Asp-Gly or EDG with bronchogen, Ala-Glu-Asp-Leu or AEDL returned 4 records, all general Khavinson peptide papers that list several peptides (for example DNA-binding and transporter work); none compares or combines the two. ClinicalTrials.gov returned no study for Chonluten or for an EDG tripeptide. openFDA Drugs@FDA and DailyMed return no product under the name. The searches found no study under the name in lung tissue, in an airway disease model, in an animal, or in a person.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

How is Chonluten thought to work?

In a human leukemia monocyte line, five Khavinson peptides including Chonluten raised tyrosine phosphorylation of mitogen-activated kinases and lowered TNF and IL-6 expression after lipopolysaccharide. That is a cell-line observation. No lung mechanism, pharmacokinetics or animal exposure is described.

In THP-1 monocytes and macrophages, all five peptides raised tyrosine phosphorylation of mitogen-activated kinases, inhibited lipopolysaccharide-stimulated TNF and IL-6 expression in differentiated cells, and reduced THP-1 adhesion to lipopolysaccharide-activated endothelial cells. The abstract says Chonluten inhibited TNF production of monocytes exposed to lipopolysaccharide.

The 2012 abstract on peptide T-34 says it regulates mRNA expression of various genes and, in gastric ulcer, normalizes synthesis of antioxidant and anti-inflammatory proteins by regulating the corresponding genes; it names no species, dose or route. None of this is a lung mechanism, and no pharmacokinetic data were found in any species.

2022 THP-1 paper: the only record under the name Chonluten

Cell study

Avolio F et al. Int J Mol Sci. 2022;23(7). PMID 35408963.

The only PubMed record that uses the name Chonluten says in its methods that Chonluten is the tripeptide Glu-Asp-Gly, and that it and two other Khavinson peptides were synthesized on the basis of their natural counterparts from animal organs. Human THP-1 monocytes and THP-1-derived macrophages were treated with 100 ng/mL of each of five Khavinson peptides, including Chonluten, alone or with 100 ng/mL lipopolysaccharide. All five peptides raised tyrosine phosphorylation of mitogen-activated kinases, inhibited lipopolysaccharide-stimulated TNF and IL-6 expression in differentiated cells, and reduced THP-1 adhesion to lipopolysaccharide-activated endothelial cells. The abstract says Chonluten inhibited TNF production of monocytes exposed to lipopolysaccharide. The results text adds that Chonluten alone produced a slight release of TNF in proliferating monocytes and that a moderate percentage of THP-1 cells showed an apoptotic profile with it. The paper calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, citing two references that are not lung studies: a 2017 study of EDR and KED peptides on neuronal spines in an Alzheimer's cell model and a 2013 study of Vilon in thymus cells.

Participants / model
Human THP-1 leukemia monocytic cell line and THP-1-derived macrophages; HUVEC endothelial cells
Treatment
Peptide at 100 ng/mL in culture medium
Follow-up
not stated in the source
Study design
Cell-line experiment series with five peptides
Funding
not stated in the source

A human leukemia cell line, not lung tissue. Chonluten was one of five peptides in a single experiment series.

Read the original source
2012 abstract: peptide T-34 in gastric ulcer

Animal study

Khavinson VKh et al. Bull Exp Biol Med. 2012;152(5):615-8. PMID 22803148.

A 2012 abstract reports that peptide T-34, described as a geroprotective peptide, regulates mRNA expression of various genes, and that in gastric ulcer it normalizes the synthesis of antioxidant and anti-inflammatory proteins by regulating the corresponding genes. The abstract does not state a species, dose, route, the sequence, or the name Chonluten. The group's 2022 table cites this paper for Chonluten as a gastroprotector, and a separate 2012 abstract gives T-34 as Glu-Asp-Gly.

Participants / model
Gastric ulcer model, species not stated in the abstract
Treatment
Not stated in the abstract
Follow-up
not stated in the source
Study design
Preclinical report
Funding
not stated in the source

The abstract does not use the name Chonluten. The link to the trade name comes from the group's 2022 table.

Read the original source
PubMed: 1 record, no clinical trial, no lung or combination study

PubMed search record

PubMed searches run 10 October 2026: chonluten[tiab]; chonluten restricted to clinical trial or randomized controlled trial publication types; chonluten, Glu-Asp-Gly or EDG combined with bronchogen, Ala-Glu-Asp-Leu or AEDL. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for chonluten[tiab] returned 1 record, the THP-1 paper, and chonluten restricted to clinical trial or randomized controlled trial publication types returned 0 records. A search combining chonluten, Glu-Asp-Gly or EDG with bronchogen, Ala-Glu-Asp-Leu or AEDL returned 4 records, all general Khavinson peptide papers that list several peptides (for example DNA-binding and transporter work); none compares or combines the two. ClinicalTrials.gov returned no study for Chonluten or for an EDG tripeptide. openFDA Drugs@FDA and DailyMed return no product under the name. The searches found no study under the name in lung tissue, in an airway disease model, in an animal, or in a person.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

What is known about the safety of Chonluten?

No human or animal safety data exist under the name Chonluten. In the one cell-line experiment, Chonluten alone produced a slight TNF release in proliferating monocytes, and a moderate percentage of THP-1 cells showed an apoptotic profile with it.

The results text of the THP-1 paper adds that Chonluten alone produced a slight release of TNF in proliferating monocytes and that a moderate percentage of THP-1 cells showed an apoptotic profile with it. These are observations in a leukemia cell line, not safety findings in tissue, animals or people.

A PubMed search on 10 October 2026 found no study under the name in an animal or a person, so there is no dose, no pharmacokinetics and no safety outcome beyond the cell-line observations.

2022 THP-1 paper: the only record under the name Chonluten

Cell study

Avolio F et al. Int J Mol Sci. 2022;23(7). PMID 35408963.

The only PubMed record that uses the name Chonluten says in its methods that Chonluten is the tripeptide Glu-Asp-Gly, and that it and two other Khavinson peptides were synthesized on the basis of their natural counterparts from animal organs. Human THP-1 monocytes and THP-1-derived macrophages were treated with 100 ng/mL of each of five Khavinson peptides, including Chonluten, alone or with 100 ng/mL lipopolysaccharide. All five peptides raised tyrosine phosphorylation of mitogen-activated kinases, inhibited lipopolysaccharide-stimulated TNF and IL-6 expression in differentiated cells, and reduced THP-1 adhesion to lipopolysaccharide-activated endothelial cells. The abstract says Chonluten inhibited TNF production of monocytes exposed to lipopolysaccharide. The results text adds that Chonluten alone produced a slight release of TNF in proliferating monocytes and that a moderate percentage of THP-1 cells showed an apoptotic profile with it. The paper calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, citing two references that are not lung studies: a 2017 study of EDR and KED peptides on neuronal spines in an Alzheimer's cell model and a 2013 study of Vilon in thymus cells.

Participants / model
Human THP-1 leukemia monocytic cell line and THP-1-derived macrophages; HUVEC endothelial cells
Treatment
Peptide at 100 ng/mL in culture medium
Follow-up
not stated in the source
Study design
Cell-line experiment series with five peptides
Funding
not stated in the source

A human leukemia cell line, not lung tissue. Chonluten was one of five peptides in a single experiment series.

Read the original source
PubMed: 1 record, no clinical trial, no lung or combination study

PubMed search record

PubMed searches run 10 October 2026: chonluten[tiab]; chonluten restricted to clinical trial or randomized controlled trial publication types; chonluten, Glu-Asp-Gly or EDG combined with bronchogen, Ala-Glu-Asp-Leu or AEDL. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for chonluten[tiab] returned 1 record, the THP-1 paper, and chonluten restricted to clinical trial or randomized controlled trial publication types returned 0 records. A search combining chonluten, Glu-Asp-Gly or EDG with bronchogen, Ala-Glu-Asp-Leu or AEDL returned 4 records, all general Khavinson peptide papers that list several peptides (for example DNA-binding and transporter work); none compares or combines the two. ClinicalTrials.gov returned no study for Chonluten or for an EDG tripeptide. openFDA Drugs@FDA and DailyMed return no product under the name. The searches found no study under the name in lung tissue, in an airway disease model, in an animal, or in a person.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Why does Chonluten sit in D tier?

One cell-line experiment is the whole record under the name, the same tripeptide was the one that did not stimulate young rat skin explants, and the group's own table gives it gastric and stress roles instead of a bronchial one. The lung claim runs ahead of the record.

Chonluten has a PubChem sequence record and exactly one PubMed record under its trade name, a leukemia cell line, plus a skin-explant result in which the same tripeptide was the one that did not stimulate proliferation in young rats. There is no lung tissue, airway disease model or human study.

The group's own classification table gives the compound gastric and stress roles rather than a bronchial one, and no record tested it with Bronchogen. The supplier claim runs ahead of what the record supports.

2022 THP-1 paper: the only record under the name Chonluten

Cell study

Avolio F et al. Int J Mol Sci. 2022;23(7). PMID 35408963.

The only PubMed record that uses the name Chonluten says in its methods that Chonluten is the tripeptide Glu-Asp-Gly, and that it and two other Khavinson peptides were synthesized on the basis of their natural counterparts from animal organs. Human THP-1 monocytes and THP-1-derived macrophages were treated with 100 ng/mL of each of five Khavinson peptides, including Chonluten, alone or with 100 ng/mL lipopolysaccharide. All five peptides raised tyrosine phosphorylation of mitogen-activated kinases, inhibited lipopolysaccharide-stimulated TNF and IL-6 expression in differentiated cells, and reduced THP-1 adhesion to lipopolysaccharide-activated endothelial cells. The abstract says Chonluten inhibited TNF production of monocytes exposed to lipopolysaccharide. The results text adds that Chonluten alone produced a slight release of TNF in proliferating monocytes and that a moderate percentage of THP-1 cells showed an apoptotic profile with it. The paper calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, citing two references that are not lung studies: a 2017 study of EDR and KED peptides on neuronal spines in an Alzheimer's cell model and a 2013 study of Vilon in thymus cells.

Participants / model
Human THP-1 leukemia monocytic cell line and THP-1-derived macrophages; HUVEC endothelial cells
Treatment
Peptide at 100 ng/mL in culture medium
Follow-up
not stated in the source
Study design
Cell-line experiment series with five peptides
Funding
not stated in the source

A human leukemia cell line, not lung tissue. Chonluten was one of five peptides in a single experiment series.

Read the original source
2012 skin explants: T-34 (Glu-Asp-Gly) did not stimulate proliferation

Cell study

Voicekhovskaya MA et al. Bull Exp Biol Med. 2012;152(3):357-9. PMID 22803085.

A 2012 abstract lists synthesized tripeptides T-32 (Glu-Asp-Ala), T-33 (Glu-Asp-Arg), T-34 (Glu-Asp-Gly), T-36 (Glu-Asp-Pro) and T-38 (Lys-Glu-Asp). In organotypic skin explants from young rats, all stimulated cell proliferation except T-34, the Glu-Asp-Gly peptide, which did not. In skin explants from old rats only T-38 produced a marked stimulatory effect.

Participants / model
Organotypic skin explants from young and old rats
Treatment
Peptides in culture medium
Follow-up
not stated in the source
Study design
Organotypic explant culture, proliferation and p53 expression
Funding
not stated in the source

A negative cell result for the same tripeptide. The study is about skin, in rats, in explants, and the abstract does not use the name Chonluten.

Read the original source
2022 table: Chonluten (EDG) listed as gastroprotector and stress protector

Narrative review

Khavinson V et al. Int J Mol Sci. 2022;23(14). PMID 35887081.

The group's 2022 table of ultrashort peptides lists Chonluten (EDG). It classifies Chonluten as a gastroprotector, citing a 2012 abstract on peptide T-34 in gastric ulcer, and as a stress protector, citing a US patent, and it lists no bronchial role. The 2022 THP-1 paper, by contrast, calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, citing two references that are not lung studies.

Participants / model
Not applicable
Treatment
Not applicable
Follow-up
not stated in the source
Study design
Review table
Funding
not stated in the source

The group's own classification gives Chonluten gastric and stress roles, not a bronchial one.

Read the original source
PubMed: 1 record, no clinical trial, no lung or combination study

PubMed search record

PubMed searches run 10 October 2026: chonluten[tiab]; chonluten restricted to clinical trial or randomized controlled trial publication types; chonluten, Glu-Asp-Gly or EDG combined with bronchogen, Ala-Glu-Asp-Leu or AEDL. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for chonluten[tiab] returned 1 record, the THP-1 paper, and chonluten restricted to clinical trial or randomized controlled trial publication types returned 0 records. A search combining chonluten, Glu-Asp-Gly or EDG with bronchogen, Ala-Glu-Asp-Leu or AEDL returned 4 records, all general Khavinson peptide papers that list several peptides (for example DNA-binding and transporter work); none compares or combines the two. ClinicalTrials.gov returned no study for Chonluten or for an EDG tripeptide. openFDA Drugs@FDA and DailyMed return no product under the name. The searches found no study under the name in lung tissue, in an airway disease model, in an animal, or in a person.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Studies and sources

PubChem: Glu-Asp-Gly tripeptide identity

Chemical identity record

National Library of Medicine. PubChem compound record CID 194641.

A PubChem name search for Chonluten returned no record. The tripeptide Glu-Asp-Gly is CID 194641, C11H17N3O8, molecular weight 319.27, CAS 75007-24-8, and its synonym list includes T-34 tripeptide. A 2012 abstract from the group defines its laboratory code T-34 as Glu-Asp-Gly (PMID 22803085). The trade name Chonluten is tied to the sequence by the literature, not by PubChem.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined synthetic peptide
Follow-up
Not applicable
Study design
NLM chemical record
Funding
not stated in the source

The record defines the sequence. It does not carry the name Chonluten.

Read the original source
2022 THP-1 paper: the only record under the name Chonluten

Cell study

Avolio F et al. Int J Mol Sci. 2022;23(7). PMID 35408963.

The only PubMed record that uses the name Chonluten says in its methods that Chonluten is the tripeptide Glu-Asp-Gly, and that it and two other Khavinson peptides were synthesized on the basis of their natural counterparts from animal organs. Human THP-1 monocytes and THP-1-derived macrophages were treated with 100 ng/mL of each of five Khavinson peptides, including Chonluten, alone or with 100 ng/mL lipopolysaccharide. All five peptides raised tyrosine phosphorylation of mitogen-activated kinases, inhibited lipopolysaccharide-stimulated TNF and IL-6 expression in differentiated cells, and reduced THP-1 adhesion to lipopolysaccharide-activated endothelial cells. The abstract says Chonluten inhibited TNF production of monocytes exposed to lipopolysaccharide. The results text adds that Chonluten alone produced a slight release of TNF in proliferating monocytes and that a moderate percentage of THP-1 cells showed an apoptotic profile with it. The paper calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, citing two references that are not lung studies: a 2017 study of EDR and KED peptides on neuronal spines in an Alzheimer's cell model and a 2013 study of Vilon in thymus cells.

Participants / model
Human THP-1 leukemia monocytic cell line and THP-1-derived macrophages; HUVEC endothelial cells
Treatment
Peptide at 100 ng/mL in culture medium
Follow-up
not stated in the source
Study design
Cell-line experiment series with five peptides
Funding
not stated in the source

A human leukemia cell line, not lung tissue. Chonluten was one of five peptides in a single experiment series.

Read the original source
2022 table: Chonluten (EDG) listed as gastroprotector and stress protector

Narrative review

Khavinson V et al. Int J Mol Sci. 2022;23(14). PMID 35887081.

The group's 2022 table of ultrashort peptides lists Chonluten (EDG). It classifies Chonluten as a gastroprotector, citing a 2012 abstract on peptide T-34 in gastric ulcer, and as a stress protector, citing a US patent, and it lists no bronchial role. The 2022 THP-1 paper, by contrast, calls Chonluten a synthetic bronchial bio-regulator with the respiratory system as its principal target, citing two references that are not lung studies.

Participants / model
Not applicable
Treatment
Not applicable
Follow-up
not stated in the source
Study design
Review table
Funding
not stated in the source

The group's own classification gives Chonluten gastric and stress roles, not a bronchial one.

Read the original source
2012 abstract: peptide T-34 in gastric ulcer

Animal study

Khavinson VKh et al. Bull Exp Biol Med. 2012;152(5):615-8. PMID 22803148.

A 2012 abstract reports that peptide T-34, described as a geroprotective peptide, regulates mRNA expression of various genes, and that in gastric ulcer it normalizes the synthesis of antioxidant and anti-inflammatory proteins by regulating the corresponding genes. The abstract does not state a species, dose, route, the sequence, or the name Chonluten. The group's 2022 table cites this paper for Chonluten as a gastroprotector, and a separate 2012 abstract gives T-34 as Glu-Asp-Gly.

Participants / model
Gastric ulcer model, species not stated in the abstract
Treatment
Not stated in the abstract
Follow-up
not stated in the source
Study design
Preclinical report
Funding
not stated in the source

The abstract does not use the name Chonluten. The link to the trade name comes from the group's 2022 table.

Read the original source
2012 skin explants: T-34 (Glu-Asp-Gly) did not stimulate proliferation

Cell study

Voicekhovskaya MA et al. Bull Exp Biol Med. 2012;152(3):357-9. PMID 22803085.

A 2012 abstract lists synthesized tripeptides T-32 (Glu-Asp-Ala), T-33 (Glu-Asp-Arg), T-34 (Glu-Asp-Gly), T-36 (Glu-Asp-Pro) and T-38 (Lys-Glu-Asp). In organotypic skin explants from young rats, all stimulated cell proliferation except T-34, the Glu-Asp-Gly peptide, which did not. In skin explants from old rats only T-38 produced a marked stimulatory effect.

Participants / model
Organotypic skin explants from young and old rats
Treatment
Peptides in culture medium
Follow-up
not stated in the source
Study design
Organotypic explant culture, proliferation and p53 expression
Funding
not stated in the source

A negative cell result for the same tripeptide. The study is about skin, in rats, in explants, and the abstract does not use the name Chonluten.

Read the original source
PubMed: 1 record, no clinical trial, no lung or combination study

PubMed search record

PubMed searches run 10 October 2026: chonluten[tiab]; chonluten restricted to clinical trial or randomized controlled trial publication types; chonluten, Glu-Asp-Gly or EDG combined with bronchogen, Ala-Glu-Asp-Leu or AEDL. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for chonluten[tiab] returned 1 record, the THP-1 paper, and chonluten restricted to clinical trial or randomized controlled trial publication types returned 0 records. A search combining chonluten, Glu-Asp-Gly or EDG with bronchogen, Ala-Glu-Asp-Leu or AEDL returned 4 records, all general Khavinson peptide papers that list several peptides (for example DNA-binding and transporter work); none compares or combines the two. ClinicalTrials.gov returned no study for Chonluten or for an EDG tripeptide. openFDA Drugs@FDA and DailyMed return no product under the name. The searches found no study under the name in lung tissue, in an airway disease model, in an animal, or in a person.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Why is Chonluten in D tier?

D fits a compound with one cell-line experiment under its name and a lung claim that its own source papers do not support. The paper that tested it used a human leukemia line and cited two non-lung references for a respiratory role, the same tripeptide did not stimulate young rat skin explants, and no study tested it in lung tissue, an airway disease model or a person.